维生素E治疗轻度认知功能障碍的临床疗效观察(1)
 |
| 第1页 |
参见附件。
[摘要] 目的 观察维生素E治疗轻度认知功能障碍的临床疗效。方法 35例轻度认知功能障碍患者随机分为两组，治疗组用维生素E联合多奈哌齐治疗(18例)，对照组单用多奈哌齐治疗(17例)。采用简易精神状况检查量表评分评估临床疗效。随访时间为2年。结果 34例患者完成临床随访，简易精神状况检查量表评分治疗组治疗前27.1±2.9分，治疗后评分29±1.6分，治疗前后比较差异有统计学意义(p<0.05)；对照组治疗前评分26.9±3分，治疗后评分27.8±2.5分，治疗前后差异有统计学意义(p<0.05)。治疗组和对照组治疗后评分比较差异有统计学意义(p<0.05)。治疗组有效率为77.8%，对照组有效率44.1%，两组差异有统计学意义(X2=4.88，p=0.027)。两组均为严重不良反应发生。结论 生素E联合多奈哌齐治疗轻度认识功能障碍疗效优于单用多奈哌齐，安全性好。
[关键词] 维生素E； 多奈哌齐； 轻度认知功能障碍
[中图分类号] R591.45 [文献标识码] A [文章编号] 1005-0515(2012)-01-004-01
[Abstract] Objective To evaluate the effective of vitamin E for mild cognitive impairment. Methods Thirty five patients with mild cognitive impairment were randomly divided into two groups. The experiment group which was combined with donepezil (18 cases); the control group was treated with donepezil only (17cases). The mini-mental state examination scale score was used to assessment of clinical efficacy. All patients were follow-up 2 years. Results 34 patients completed the clinical follow-up. In experiment group, The mini-mental state examination scale score before treatment was 27.1 ± 2.9,post-treatment score was 29 ± 1.6,before and after treatment difference was statistically significant (p <0.05); in control group, before treatment score was 26.9 ± 3, post-treatment score was 27.8 ± 2.5, before and after treatment difference was statistically significant (p <0.05). The difference of post-treatment score between experiment and control group was statistically significant (p <0.05). The effect rate in experiment group was 77.8% in control group was 44.1%, the difference was statistically significant (χ2 = 4.88, p = 0.027). There were no serious adverse events in the two groups. Conclusion The effect of Vitamin E combined with donepezil for mild cognitive impairment was better than donepezil only.
[Key words] Vitamin E；Donepezil; Mild cognitive impairment
一般认为轻度认知功能障碍(mildcognitiveimpairment，MCI)是介于正常老化和痴呆之间的一种临床状态，处于这种状态的个体存在超出其年龄所允许的记忆障碍，但仍能维持功能完好，达不到痴呆的诊断标准[1]。大于65岁的人群中约有10-20%轻度认知障碍患者。一般认为轻度认知障碍有两种亚型，遗忘型和非遗忘型。前者主要表现为记忆功能受损，与Alzheimer症发病密切相关，临床资料显示约90%的遗忘型MCI患者会出现Alzheimer症的表现[2]。虽然美国食品药品监督局尚未批准治疗MCI的药物，但目前多采用治疗痴呆的药物，如乙酰胆碱酯酶抑制剂、益智药、非胆固醇类抗炎药用于治疗轻度认知功能障碍[3] ......
您现在查看是摘要介绍页，详见PDF附件(2800kb)。